U.S. Markets open in 7 hrs 8 mins

Nuvo Pharmaceuticals Inc. (NRI.TO)


Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
4.35-0.02 (-0.46%)
At close: 2:32PM EDT
Interactive chart
Previous Close4.37
Open4.31
Bid4.36 x
Ask4.58 x
Day's Range4.31 - 4.38
52 Week Range3.95 - 8.35
Volume3,375
Avg. Volume36,900
Market Cap50.25M
Beta-0.05
PE Ratio (TTM)12.15
EPS (TTM)0.36
Earnings DateAug 8, 2017 - Aug 14, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • CNW Group10 days ago

    Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%

    Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%

  • PR Newswire10 days ago

    Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%

    MISSISSAUGA, ON, May 15, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today reported topline results from its multi-centre, randomized, placebo-controlled, double-blind, parallel group trial in patients, with grade I or II ankle sprains (the Trial) and in particular reported that the Trial had failed to meet its primary endpoint.

  • PR Newswire10 days ago

    Nuvo Pharmaceuticals™ Announces District Court Decision to Uphold U.S. Pennsaid® 2% Patent

    MISSISSAUGA, ON, May 15, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that the United States District Court for the District of New Jersey has upheld the validity of Horizon Pharma plc's (Horizon) (HZNP) U.S. patent covering Pennsaid® (diclofenac sodium topical solution) 2% w/w (Pennsaid 2%), which Actavis Laboratories UT, Inc. (Actavis) has admitted that its proposed generic version of Pennsaid 2% would infringe.  Nuvo earns revenue by selling commercial bottles and physician samples of Pennsaid 2% to Horizon under an exclusive manufacturing and supply agreement that extends to 2029. On July 6, 2015, Horizon filed a patent infringement lawsuit in District Court against Actavis related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration (FDA) to market a generic version of Pennsaid 2% in the U.S.  The lawsuit claims infringement of Horizon's U.S. Patent No. 9,066,913 ('913 patent) titled "Diclofenac Topical Formulation," which covers Pennsaid 2%.  Horizon has advised Nuvo that the District Court's decision was made based on the validity of Horizon's '913 patent for Pennsaid 2% and that the Court's judgement will prevent Actavis from launching a generic version of Pennsaid 2% in the United States.